Given the intersection between diabetes mellitus and cardiovascular disease (CVD),
pharmacologic agents used to treat type 2 diabetes mellitus must show cardiovascular …

Recent large clinical trials on sodium-glucose cotransporter 2 (SGLT2) inhibitors and
glucagon-like peptide-1 (GLP-1) receptor agonists, with the aim of verifying cardiovascular …

Diabetes is a leading cause of morbidity and mortality worldwide. Management of diabetes
is changing at a rapid pace. Three new classes of antidiabetic drugs including GLP-1 …

Type 2 Diabetes Mellitus (T2DM) is associated with a high risk of atherosclerotic
cardiovascular (CV) disease. Among the well-known pathophysiologic factors, crucial roles …

Key Clinical Points Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2
Diabetes The attainment of glycemic targets and comprehensive reduction in risk factors for …

Type 2 diabetes mellitus is a major risk factor for developing cardiovascular disease, and
many patients with diabetes have prevalent cardiovascular complications. Recent …

The growing global burden of type 2 diabetes mellitus confers significant morbidity and
mortality in addition to significant cost to local health-care systems. In recent years, 2 classes …

Recently, treatment with 2 newer classes of type 2 diabetes drugs were found to reduce
events in patients with diabetes and cardiovascular (CV) disease, a group common in …

The risk of cardiovascular disease (CVD)(myocardial infarction, stroke, peripheral vascular
disease) is twice in type 2 diabetes (T2D) patients compared to non-diabetic subjects …

Background: Glucagon-like peptide 1 receptor agonists (GLP1-RA) and sodium-glucose
cotransporter-2 inhibitors (SGLT2i) have emerged as 2 new classes of antihyperglycemic …